Loading...
Loading...
EVLO| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.0M |
| Operating Expense | 24.9M |
| Operating I/L | -24.9M |
| Other Income/Expense | -0.3M |
| Interest Income | 0.0M |
| Pretax | -25.2M |
| Income Tax Expense | 0.1M |
| Net Income/Loss | -25.3M |
Evelo Biosciences, Inc. is a biotechnology company specializing in the discovery and development of oral biologics for the treatment of inflammatory diseases and cancer. The company's lead candidate, EDP1815, is in Phase 2 clinical trials for psoriasis, atopic dermatitis, and the hyperinflammatory response associated with COVID-19. Additionally, Evelo Biosciences is developing EDP1867, EDP2939, and EDP1908 for the treatment of inflammatory diseases and oncology.
